Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain.

Emptage RP, Lemmon MA, Ferguson KM, Marmorstein R.

Structure. 2018 Aug 7;26(8):1137-1143.e3. doi: 10.1016/j.str.2018.05.008. Epub 2018 Jun 28.

PMID:
30099988
2.

Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23.

Liu L, Thaker TM, Freed DM, Frazier N, Malhotra K, Lemmon MA, Jura N.

Structure. 2018 Feb 6;26(2):270-281.e4. doi: 10.1016/j.str.2017.12.012. Epub 2018 Jan 18.

PMID:
29358026
3.

Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling.

Lee S, Choi J, Mohanty J, Sousa LP, Tome F, Pardon E, Steyaert J, Lemmon MA, Lax I, Schlessinger J.

Nature. 2018 Jan 25;553(7689):501-505. doi: 10.1038/nature25010. Epub 2018 Jan 17.

PMID:
29342135
4.

EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.

Freed DM, Bessman NJ, Kiyatkin A, Salazar-Cavazos E, Byrne PO, Moore JO, Valley CC, Ferguson KM, Leahy DJ, Lidke DS, Lemmon MA.

Cell. 2017 Oct 19;171(3):683-695.e18. doi: 10.1016/j.cell.2017.09.017. Epub 2017 Oct 5.

PMID:
28988771
5.

Dimerization of Tie2 mediated by its membrane-proximal FNIII domains.

Moore JO, Lemmon MA, Ferguson KM.

Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4382-4387. doi: 10.1073/pnas.1617800114. Epub 2017 Apr 10.

6.

Molecular determinants of KA1 domain-mediated autoinhibition and phospholipid activation of MARK1 kinase.

Emptage RP, Lemmon MA, Ferguson KM.

Biochem J. 2017 Feb 1;474(3):385-398. doi: 10.1042/BCJ20160792. Epub 2016 Nov 22.

7.

Overcoming resistance to HER2 inhibitors through state-specific kinase binding.

Novotny CJ, Pollari S, Park JH, Lemmon MA, Shen W, Shokat KM.

Nat Chem Biol. 2016 Nov;12(11):923-930. doi: 10.1038/nchembio.2171. Epub 2016 Sep 5.

8.

Deletion Mutations Keep Kinase Inhibitors in the Loop.

Freed DM, Park JH, Radhakrishnan R, Lemmon MA.

Cancer Cell. 2016 Apr 11;29(4):423-425. doi: 10.1016/j.ccell.2016.03.017.

9.

The Dark Side of Cell Signaling: Positive Roles for Negative Regulators.

Lemmon MA, Freed DM, Schlessinger J, Kiyatkin A.

Cell. 2016 Mar 10;164(6):1172-1184. doi: 10.1016/j.cell.2016.02.047. Review.

10.

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

Infarinato NR, Park JH, Krytska K, Ryles HT, Sano R, Szigety KM, Li Y, Zou HY, Lee NV, Smeal T, Lemmon MA, Mossé YP.

Cancer Discov. 2016 Jan;6(1):96-107. doi: 10.1158/2159-8290.CD-15-1056. Epub 2015 Nov 10.

11.

EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features.

Ganetzky R, Finn E, Bagchi A, Zollo O, Conlin L, Deardorff M, Harr M, Simpson MA, McGrath JA, Zackai E, Lemmon MA, Sondheimer N.

Mol Genet Genomic Med. 2015 Sep;3(5):452-8. doi: 10.1002/mgg3.156. Epub 2015 Jun 4.

12.

Ligand regulation of a constitutively dimeric EGF receptor.

Freed DM, Alvarado D, Lemmon MA.

Nat Commun. 2015 Jun 10;6:7380. doi: 10.1038/ncomms8380.

13.

Comparison of Saccharomyces cerevisiae F-BAR domain structures reveals a conserved inositol phosphate binding site.

Moravcevic K, Alvarado D, Schmitz KR, Kenniston JA, Mendrola JM, Ferguson KM, Lemmon MA.

Structure. 2015 Feb 3;23(2):352-63. doi: 10.1016/j.str.2014.12.009. Epub 2015 Jan 22.

14.

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP.

Cancer Cell. 2014 Nov 10;26(5):682-94. doi: 10.1016/j.ccell.2014.09.019. Epub 2014 Nov 10.

15.

Putting together structures of epidermal growth factor receptors.

Bessman NJ, Freed DM, Lemmon MA.

Curr Opin Struct Biol. 2014 Dec;29:95-101. doi: 10.1016/j.sbi.2014.10.002. Epub 2014 Oct 24. Review.

16.

Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor.

Bessman NJ, Bagchi A, Ferguson KM, Lemmon MA.

Cell Rep. 2014 Nov 20;9(4):1306-17. doi: 10.1016/j.celrep.2014.10.010. Epub 2014 Nov 6.

17.

TIPE3 is the transfer protein of lipid second messengers that promote cancer.

Fayngerts SA, Wu J, Oxley CL, Liu X, Vourekas A, Cathopoulis T, Wang Z, Cui J, Liu S, Sun H, Lemmon MA, Zhang L, Shi Y, Chen YH.

Cancer Cell. 2014 Oct 13;26(4):465-78. doi: 10.1016/j.ccr.2014.07.025. Epub 2014 Sep 18.

18.

The EGFR family: not so prototypical receptor tyrosine kinases.

Lemmon MA, Schlessinger J, Ferguson KM.

Cold Spring Harb Perspect Biol. 2014 Apr 1;6(4):a020768. doi: 10.1101/cshperspect.a020768. Review.

19.

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer.

Red Brewer M, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W.

Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):E3595-604. doi: 10.1073/pnas.1220050110. Epub 2013 Sep 9. Erratum in: Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20344.

20.

Receptor tyrosine kinases with intracellular pseudokinase domains.

Mendrola JM, Shi F, Park JH, Lemmon MA.

Biochem Soc Trans. 2013 Aug;41(4):1029-36. doi: 10.1042/BST20130104. Review.

21.

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain.

Park JH, Liu Y, Lemmon MA, Radhakrishnan R.

Biochem J. 2012 Dec 15;448(3):417-23. doi: 10.1042/BJ20121513.

22.

Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family.

Artim SC, Mendrola JM, Lemmon MA.

Biochem J. 2012 Dec 1;448(2):213-20. doi: 10.1042/BJ20121365.

23.

Occupy EGFR.

Park JH, Lemmon MA.

Cancer Discov. 2012 May;2(5):398-400. doi: 10.1158/2159-8290.CD-12-0144.

24.

Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.

Carpenter EL, Haglund EA, Mace EM, Deng D, Martinez D, Wood AC, Chow AK, Weiser DA, Belcastro LT, Winter C, Bresler SC, Vigny M, Mazot P, Asgharzadeh S, Seeger RC, Zhao H, Guo R, Christensen JG, Orange JS, Pawel BR, Lemmon MA, Mossé YP.

Oncogene. 2012 Nov 15;31(46):4859-67. doi: 10.1038/onc.2011.647. Epub 2012 Jan 23. Erratum in: Oncogene. 2012 Nov 15;31(46):4888. Vigny, M [added]; Mazot, P [added].

25.

Finding the missing links in EGFR.

Bessman NJ, Lemmon MA.

Nat Struct Mol Biol. 2012 Jan 5;19(1):1-3. doi: 10.1038/nsmb.2221. No abstract available.

PMID:
22218287
26.

Conditional peripheral membrane proteins: facing up to limited specificity.

Moravcevic K, Oxley CL, Lemmon MA.

Structure. 2012 Jan 11;20(1):15-27. doi: 10.1016/j.str.2011.11.012. Epub 2011 Dec 21. Review.

27.

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, Cole K, Toporovskaya Y, Zhao H, Carpenter EL, Christensen JG, Maris JM, Lemmon MA, Mossé YP.

Sci Transl Med. 2011 Nov 9;3(108):108ra114. doi: 10.1126/scitranslmed.3002950.

28.

Mutations in or near the transmembrane domain alter PMEL amyloid formation from functional to pathogenic.

Watt B, Tenza D, Lemmon MA, Kerje S, Raposo G, Andersson L, Marks MS.

PLoS Genet. 2011 Sep;7(9):e1002286. doi: 10.1371/journal.pgen.1002286. Epub 2011 Sep 15.

29.

Biochemistry. KSR plays CRAF-ty.

Shi F, Lemmon MA.

Science. 2011 May 27;332(6033):1043-4. doi: 10.1126/science.1208063. No abstract available.

PMID:
21617065
30.

Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases.

Shih AJ, Telesco SE, Choi SH, Lemmon MA, Radhakrishnan R.

Biochem J. 2011 Jun 1;436(2):241-51. doi: 10.1042/BJ20101791.

31.

Protein kinase C regulation: C1 meets C-tail.

Kazanietz MG, Lemmon MA.

Structure. 2011 Feb 9;19(2):144-6. doi: 10.1016/j.str.2011.01.004.

32.

Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer.

Sosa MS, Lopez-Haber C, Yang C, Wang H, Lemmon MA, Busillo JM, Luo J, Benovic JL, Klein-Szanto A, Yagi H, Gutkind JS, Parsons RE, Kazanietz MG.

Mol Cell. 2010 Dec 22;40(6):877-92. doi: 10.1016/j.molcel.2010.11.029.

33.

Kinase associated-1 domains drive MARK/PAR1 kinases to membrane targets by binding acidic phospholipids.

Moravcevic K, Mendrola JM, Schmitz KR, Wang YH, Slochower D, Janmey PA, Lemmon MA.

Cell. 2010 Dec 10;143(6):966-77. doi: 10.1016/j.cell.2010.11.028.

34.

Structural basis for negative cooperativity in growth factor binding to an EGF receptor.

Alvarado D, Klein DE, Lemmon MA.

Cell. 2010 Aug 20;142(4):568-79. doi: 10.1016/j.cell.2010.07.015.

35.

Dynamin GTPase regulation is altered by PH domain mutations found in centronuclear myopathy patients.

Kenniston JA, Lemmon MA.

EMBO J. 2010 Sep 15;29(18):3054-67. doi: 10.1038/emboj.2010.187. Epub 2010 Aug 10.

36.

Cell signaling by receptor tyrosine kinases.

Lemmon MA, Schlessinger J.

Cell. 2010 Jun 25;141(7):1117-34. doi: 10.1016/j.cell.2010.06.011. Review.

37.

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.

Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA.

Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7692-7. doi: 10.1073/pnas.1002753107. Epub 2010 Mar 29.

38.

N-terminal domains elicit formation of functional Pmel17 amyloid fibrils.

Watt B, van Niel G, Fowler DM, Hurbain I, Luk KC, Stayrook SE, Lemmon MA, Raposo G, Shorter J, Kelly JW, Marks MS.

J Biol Chem. 2009 Dec 18;284(51):35543-55. doi: 10.1074/jbc.M109.047449.

39.

Live cell imaging with protein domains capable of recognizing phosphatidylinositol 4,5-bisphosphate; a comparative study.

Szentpetery Z, Balla A, Kim YJ, Lemmon MA, Balla T.

BMC Cell Biol. 2009 Sep 21;10:67. doi: 10.1186/1471-2121-10-67.

40.

ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor.

Alvarado D, Klein DE, Lemmon MA.

Nature. 2009 Sep 10;461(7261):287-91. doi: 10.1038/nature08297. Epub 2009 Aug 30.

41.

A possible effector role for the pleckstrin homology (PH) domain of dynamin.

Bethoney KA, King MC, Hinshaw JE, Ostap EM, Lemmon MA.

Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13359-64. doi: 10.1073/pnas.0906945106. Epub 2009 Aug 3.

42.

The juxtamembrane region of the EGF receptor functions as an activation domain.

Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, Carpenter G.

Mol Cell. 2009 Jun 26;34(6):641-51. doi: 10.1016/j.molcel.2009.04.034.

43.

Role of Inn1 and its interactions with Hof1 and Cyk3 in promoting cleavage furrow and septum formation in S. cerevisiae.

Nishihama R, Schreiter JH, Onishi M, Vallen EA, Hanna J, Moravcevic K, Lippincott MF, Han H, Lemmon MA, Pringle JR, Bi E.

J Cell Biol. 2009 Jun 15;185(6):995-1012. doi: 10.1083/jcb.200903125.

44.

Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis.

Lian L, Wang Y, Flick M, Choi J, Scott EW, Degen J, Lemmon MA, Abrams CS.

Blood. 2009 Apr 9;113(15):3577-84. doi: 10.1182/blood-2008-09-178913. Epub 2009 Feb 3.

45.

Functional selectivity of EGF family peptide growth factors: implications for cancer.

Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ 2nd.

Pharmacol Ther. 2009 Apr;122(1):1-8. doi: 10.1016/j.pharmthera.2008.11.008. Epub 2008 Dec 16. Review.

46.

Ligand-induced ErbB receptor dimerization.

Lemmon MA.

Exp Cell Res. 2009 Feb 15;315(4):638-48. doi: 10.1016/j.yexcr.2008.10.024. Epub 2008 Oct 31. Review.

47.

Structural basis for EGFR ligand sequestration by Argos.

Klein DE, Stayrook SE, Shi F, Narayan K, Lemmon MA.

Nature. 2008 Jun 26;453(7199):1271-5. doi: 10.1038/nature06978. Epub 2008 May 25.

48.

Mechanism of activation and inhibition of the HER4/ErbB4 kinase.

Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, Banjade S, Pal A, Bornmann WG, Lemmon MA, Cole PA, Leahy DJ.

Structure. 2008 Mar;16(3):460-7. doi: 10.1016/j.str.2007.12.016.

49.

Membrane recognition by phospholipid-binding domains.

Lemmon MA.

Nat Rev Mol Cell Biol. 2008 Feb;9(2):99-111. doi: 10.1038/nrm2328. Review.

PMID:
18216767
50.

Ligand-induced structural transitions in ErbB receptor extracellular domains.

Dawson JP, Bu Z, Lemmon MA.

Structure. 2007 Aug;15(8):942-54.

Supplemental Content

Loading ...
Support Center